Zacks.com on MSN5h
Down -8.24% in 4 Weeks, Here's Why Regeneron (REGN) Looks Ripe for a Turnaround
A downtrend has been apparent in Regeneron (REGN) lately with too much selling pressure. The stock has declined 8.2% over the past four weeks. However, given the fact that it is now in oversold ...
FiercePharma8h
Regeneron, Sanofi 'Du More' Dupixent asthma ads, using humor to convey breathe better message
Regeneron and Sanofi are back with another push to show how Dupixent can help people with asthma “Du More.” The fourth ...
Countdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of Regeneron (REGN) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics ...
FierceBiotech4d
Regeneron signs Mammoth gene editing deal worth $100M upfront
Regeneron is signing another major deal in gene editing—and, this time, it’s Mammoth. Mammoth Biosciences, that is. The ...
FiercePharma3d
AbbVie's Rinvoq conquers Regeneron and Sanofi's Dupixent in eczema trial—again
For the second time in four years, AbbVie’s Rinvoq (upadacitinib) has shown superior efficacy to Regeneron and Sanofi’s ...
AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective ...
Making the Grade: 20 LI students qualify for Regeneron International Science and Engineering Fair
The students had competed in the Long Island Science and Engineering Fair, an annual event that received more than 400 ...
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the ...